Beau Bush brings to every client a rich background in predictive analytics, risk assessments, and valuation models for the pharmaceutical industry. He has more than 15 years of experience in developing data-based business and investment strategies, including extensive experience preparing and delivering senior-level summaries and recommendations for global investment and growth strategies.
After more than a decade working on new product development, Beau left his position as Associate Director of Strategy and Portfolio Analysis at Janssen (Johnson & Johnson) in 2013, when he saw the opportunity to engage more directly with an increasingly complex and dynamic healthcare market.
With newly emerging business models and increasing complexity in drug development making it more and more difficult to predict the impact of new products—or decide which products to pursue—Beau envisioned a company that could bring clarity and confidence to the investment decisions that shape tomorrow’s pharmaceutical products.
Beau has a BS in biology from Rutgers University and has worked in several industries, including finance, pharmaceuticals, marine biology, environmental science, and business consulting. He brings to Ozmosi a deep understanding and broad knowledge of global market valuation and healthcare product development, as well as an extensive network of industry experts.
Michael HudakData Services
Michael leads Data Services with strong background in supply chain and financial analytics. In addition to his strong analytics background he is an industry expert in clinical trial data and is often the senior analyst on our internal and client based clinical trial data analysis projects. He is highly proficient with data processing practices and tools necessary for analyzing the vast amounts of data connected to the healthcare industry. Michael was the lead developer of our Customized BEAM business intelligence tool and led the creation of the Global Clinical Trials database.
In his spare time at OZMOSI Michael leads Client Services projects too, such as pharmaceutical portfolio reviews, forecast tool development and company valuations for M&A analyses.
Michael earned his Master’s Degree in Business Administration from Salisbury University in Maryland. With this education, he brings a breadth of knowledge which is applied daily to OZMOSI’s various projects.
Molly FelterResearch Analyst / Project Manager
Molly is responsible for providing our clients with the customized and specific research and summaries that their important projects demand. When she is not busy delivering insights for our customers she is making sure our other projects are on time and on budget, she keeps things running at OZMOSI. Molly is currently finishing her Bachelor’s Degree in business.
Sonam GuptaData Scientist
Spends her days applying natural language processing techniques to the many large databases available in healthcare. Her role in aggregating and interpreting large amounts of information using machine learning algorithms supports client deliverables and is geared toward improving our already powerful forecast models. Through the addition of NLP techniques, such as part-of-speech tagging, sentiment analysis, text classification and many more, the end goal is to make smarter models over time using deep learning and advanced machine learning for text data.
Sonam Gupta comes from a machine learning and natural language processing (NLP) background, along with a computer science foundation. She has a Master’s Degree in Information Systems with a focus on data analytics from Harrisburg University in Pennsylvania.
Joe Edelmann, CFAAnalyst
Joe lends his support to both Client and Data Services, with a passion for data and a strong background in financial analysis and modeling. Prior to joining OZMOSI, Joe was a Senior Analyst at the Princeton University Investment Company, where he helped evaluate the University’s investments in real estate, natural resources, and private equity. He earned his Bachelor’s Degree in Economics from Princeton University, and the CFA charter in 2017.